R1 Therapeutics
PrivateLast Round
Series A
Mar 17, 2026
Total Funding Raised
$77.5M
Company Overview
R1 Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of first-in-class therapies for patients with kidney disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
R1 Therapeutics Comps
Public and private peers based on sector, stage, and business model.
R1 Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 17, 2026 |
R1 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series A |
| Abingworth | Series A |
| F-Prime Capital | Series A |
| DaVita Venture Group | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
$78M round completed.
R1 Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about R1 Therapeutics's valuation, stock price, and market status.
